Approved January 2006
Ranexa (ranolazine) is an orally-available, extended release anti-ischemic/anti-anginal drug, designed to act without reducing heart rate or blood pressure.
Ranexa is specifically indicated for the treatment of chronic angina in patients who have failed to respond to prior angina therapy. It is contraindicated in patients with pre-existing QT interval prolongation (see Side Effects section, below).
Ranexa is supplied as a film-coated extended release tablet. Recommended initial dosing is 500 mg twice daily; this may be escalated to a maximum dose of 1000 mg twice daily, based on disease response.
Approval of Ranexa was based on a pair of clinical trials, dubbed ERICA (Efficacy of Ranolazine In Chronic Angina) and CARISA (Combination Assessment of Ranolazine In Stable Angina).
In this placebo controlled study, 565 patients were randomized to receive a 1 week loading regimen of 500 mg Ranexa or placebo twice daily, followed by a 6 week regimen of 1000 mg Ranexa or placebo twice daily, in combination with 10 mg amlodipine once daily. Trial data showed that Ranexa significantly decreased frequency of angina attacks (mean 3.3 attacks per week, vs. 4.3 for placebo; p=0.028) and need for intervention treatment with nitroglycerin (mean 2.7 doses per week, vs. 3.6 for placebo; p=0.014). The drug was seen to have higher efficacy in male patients.
This placebo controlled study enrolled 823 patients, who received one of two twice daily doses of Ranexa (750 mg or 1000 mg) or placebo, in combination with continued background therapy (50 mg atenolol, 5 mg amlodipine, or 180 mg diltiazem CD). Trial data yielded a significant increase in modified Bruce treadmill exercise tolerance (p<0.05) and time to angina onset (p<0.05) at both peak (4 hours post dose) and trough (12 hours post dose) drug plasma concentrations. Both doses significantly reduced angina frequency (750 mg: 2.5 attacks/week; 1000 mg: 2.1 attacks/week; vs. 3.3 attacks/week for placebo; p=0.006 and p<0.001, respectively) and nitroglycerin intervention (750 mg: 2.1 doses/week; 1000 mg: 1.8 doses/week; vs. 3.1 doses/week for placebo; p=0.016 and p<0.001). There was no significant difference in efficacy between the two doses of Ranexa.
Ongoing Study Commitments
Adverse events associated with the use of Ranexa may include, but are not limited to, the following:
In addition, Ranexa was shown to dose-dependently prolong cardiac QTc interval; this prolongation was independent of age, weight, gender, race, heart rate, CHF NYHA Class I to IV, and diabetic status. Other drugs associated with significant QTc prolongation have been associated with torsades de pointes-type arrhythmias and sudden death. Further, the drug's QTc-prolonging effects are increased in patients with hepatic dysfunction, and in patients on medication which inhibits the metabolic enzyme CYP3A. Ranolazine is contra-indicated for subjects with existing QTc prolongations, in patients with all-grade liver disease and in patients on drugs which inhibit CYP3A (including azole antibiotics, macrolide antibiotics, HIV protease inhibitor, and others). Subjects are advised to monitor symptoms of QTc prolongation closely, in collaboration with their physicians.
Ranexa's mechanism of action has not been fully characterized. The drug has been shown to exert its anti-anginal and anti-ischemic effects without reducing heart rate or blood pressue. The drug does not increase the rate-pressure product at maximal exercise levels. It is suspected that the drug exerts some of its effects by eliciting changes in cardiac metabolism.
For additional information regarding Ranexa or Chronic Angina, please visit the Ranexa web page.
The Ranexa drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.